Losartan/hydrochlorothiazide

Losartan/hydrochlorothiazide
Combination of
Losartan Angiotensin II receptor antagonist
Hydrochlorothiazide Thiazide diuretic
Clinical data
Trade names Anzaplus, Cozaar comp, Hyzaar, Ocsaar Plus
Pregnancy
category
  • US: D (Evidence of risk)
    Routes of
    administration    		 Oral
    ATC code
    Legal status
    Legal status
    • In general: ℞ (Prescription only)
    Identifiers
    PubChem CID
    KEGG

    Losartan/hydrochlorothiazide is a combination drug used as an antihypertensive, consisting of losartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a diuretic).

    The losartan/hydrochlorothiazide combination preparation is marketed by Merck under the trade name Hyzaar and by Xeno Pharmaceuticals under the name Anzaplus. Merck, Sharp & Dohme market it as Ocsaar Plus in Israel. It is marketed as Cozaar comp in Sweden and South Africa.

    In 2010, the patent for the combination expired, and a number of pharmaceutical companies promptly filed and received approval to sell the generic losartan, with and without hydrochlorothiazide, in the United States.[1]

    Dosage

    The recommended dosage of losartan-hydrochlorothiazide for adults with high blood pressure (hypertension) will vary between losartan-hydrochlorothiazide 50 mg/12.5 mg and losartan-hydrochlorothiazide 100 mg/25 mg once a day. Based on the initial blood pressure response and/or losartan-hydrochlorothiazide side effects, the dosage may be increased or decreased. With each change in dosage, it may take up to a month to see the full effect of losartan-hydrochlorothiazide on lowering blood pressure.

    References

    1. ↑ "Teva Announces Final Approval of Generic Hyzaar and Cozaar". MarketWatch. Archived from the original on April 29, 2010. Retrieved August 18, 2018.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.